Balchem (BCPC) | Financial Analysis & Statements
Balchem Corporation Mid-cap Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
263.6M
Gross Profit
93.9M
35.62%
Operating Income
52.3M
19.84%
Net Income
39.2M
14.88%
EPS (Diluted)
$1.21
Balance Sheet Metrics
Total Assets
1.7B
Total Liabilities
428.8M
Shareholders Equity
1.3B
Debt to Equity
0.34
Cash Flow Metrics
Operating Cash Flow
47.7M
Free Cash Flow
51.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Balchem Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.0B | 953.7M | 922.4M | 942.4M | 799.0M |
| Cost of Goods Sold | 666.5M | 617.5M | 620.4M | 661.9M | 555.8M |
| Gross Profit | 370.6M | 336.2M | 302.1M | 280.5M | 243.2M |
| Gross Margin % | 35.7% | 35.3% | 32.7% | 29.8% | 30.4% |
| Operating Expenses | |||||
| Research & Development | 18.5M | 16.8M | 15.0M | 12.2M | 13.5M |
| Selling, General & Administrative | 142.8M | 136.5M | 127.8M | 123.1M | 102.1M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 161.3M | 153.3M | 142.9M | 135.3M | 115.7M |
| Operating Income | 209.3M | 182.9M | 159.2M | 145.2M | 127.5M |
| Operating Margin % | 20.2% | 19.2% | 17.3% | 15.4% | 16.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 10.2M | 16.5M | 22.6M | 10.3M | 2.5M |
| Other Non-Operating Income | -77.0K | 72.0K | 681.0K | -1.2M | 187.0K |
| Pre-tax Income | 199.0M | 166.5M | 137.3M | 133.7M | 125.2M |
| Income Tax | 44.2M | 38.0M | 28.7M | 28.4M | 29.1M |
| Effective Tax Rate % | 22.2% | 22.8% | 20.9% | 21.2% | 23.3% |
| Net Income | 154.8M | 128.5M | 108.5M | 105.4M | 96.1M |
| Net Margin % | 14.9% | 13.5% | 11.8% | 11.2% | 12.0% |
| Key Metrics | |||||
| EBITDA | 254.9M | 231.0M | 214.8M | 195.9M | 176.6M |
| EPS (Basic) | - | $3.95 | $3.37 | $3.28 | $2.98 |
| EPS (Diluted) | - | $3.93 | $3.35 | $3.25 | $2.94 |
| Basic Shares Outstanding | - | 32527244 | 32254728 | 32152787 | 32287150 |
| Diluted Shares Outstanding | - | 32527244 | 32254728 | 32152787 | 32287150 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Balchem Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 74.6M | 49.5M | 64.4M | 66.6M | 103.2M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 143.6M | 119.7M | 125.3M | 131.6M | 117.4M |
| Inventory | 131.4M | 130.8M | 109.5M | 119.7M | 91.1M |
| Other Current Assets | 6.2M | 5.7M | 7.2M | 7.1M | 4.4M |
| Total Current Assets | 365.6M | 313.8M | 314.2M | 335.8M | 322.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 356.5M | 332.1M | 332.6M | 298.3M | 9.3M |
| Goodwill | 1.8B | 1.7B | 1.7B | 1.8B | 1.1B |
| Intangible Assets | 163.3M | 165.0M | 191.2M | 213.3M | 94.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 18.1M | 17.3M | 16.9M | 15.1M | 11.7M |
| Total Non-Current Assets | 1.3B | 1.3B | 1.3B | 1.3B | 877.1M |
| Total Assets | 1.7B | 1.6B | 1.6B | 1.6B | 1.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 60.4M | 54.7M | 55.5M | 57.3M | 56.2M |
| Short-term Debt | 3.8M | 3.3M | 4.2M | 4.0M | 2.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 176.4M | 157.7M | 148.5M | 140.0M | 143.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 176.9M | 204.7M | 326.1M | 456.6M | 115.7M |
| Deferred Tax Liabilities | 54.1M | 43.7M | 52.0M | 62.8M | 46.5M |
| Other Non-Current Liabilities | 21.4M | 19.3M | 16.6M | 26.8M | 13.7M |
| Total Non-Current Liabilities | 252.5M | 267.8M | 394.7M | 546.2M | 178.5M |
| Total Liabilities | 428.8M | 425.5M | 543.2M | 686.2M | 322.3M |
| Equity | |||||
| Common Stock | 2.1M | 2.2M | 2.2M | 2.1M | 2.2M |
| Retained Earnings | 1.1B | 997.5M | 897.5M | 814.5M | 732.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.3B | 1.1B | 1.1B | 938.3M | 877.0M |
| Key Metrics | |||||
| Total Debt | 180.7M | 208.0M | 330.3M | 460.6M | 118.0M |
| Working Capital | 189.2M | 156.1M | 165.8M | 195.8M | 178.4M |
Balance Sheet Composition
Balchem Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 154.8M | 128.5M | 108.5M | 105.4M | 96.1M |
| Depreciation & Amortization | 45.7M | 48.0M | 54.9M | 51.8M | 48.9M |
| Stock-Based Compensation | 18.1M | 16.7M | 16.1M | 13.2M | 10.8M |
| Working Capital Changes | -17.4M | -15.4M | 20.0M | -11.5M | -35.3M |
| Operating Cash Flow | 207.4M | 170.8M | 177.4M | 150.5M | 114.6M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | -676.0K | -24.4M | -1.5M | -366.3M | -86.0K |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 0 | 0 | 2.7M | 0 | 0 |
| Investing Cash Flow | -402.0K | -24.1M | 3.1M | -366.1M | 2.1M |
| Financing Activities | |||||
| Share Repurchases | -107.6M | -5.7M | -4.5M | -35.4M | -35.2M |
| Dividends Paid | -28.3M | -25.6M | -22.9M | -20.7M | -18.7M |
| Debt Issuance | 88.0M | 26.0M | 18.0M | 435.0M | 5.0M |
| Debt Repayment | -114.2M | -145.8M | -149.2M | -134.2M | -60.2M |
| Financing Cash Flow | -162.1M | -151.0M | -158.6M | 243.5M | -109.1M |
| Free Cash Flow | 173.1M | 146.3M | 145.9M | 88.6M | 123.2M |
| Net Change in Cash | 44.9M | -4.3M | 21.9M | 27.9M | 7.5M |
Cash Flow Trend
Balchem Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
36.99
Forward P/E
28.92
Price to Book
4.48
Price to Sales
5.49
PEG Ratio
2.00
Profitability Ratios
Profit Margin
14.93%
Operating Margin
19.84%
Return on Equity
12.86%
Return on Assets
8.02%
Financial Health
Current Ratio
2.07
Debt to Equity
14.37
Beta
0.95
Per Share Data
EPS (TTM)
$4.75
Book Value per Share
$39.22
Revenue per Share
$32.15
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BCPC | 5.7B | 36.99 | 4.48 | 12.86% | 14.93% | 14.37 |
| Linde plc | 236.5B | 34.73 | 6.16 | 17.82% | 20.30% | 70.63 |
| Sherwin-Williams | 83.7B | 32.88 | 18.09 | 59.39% | 10.90% | 306.06 |
| Element Solutions | 9.3B | 48.25 | 3.46 | 7.51% | 7.48% | 64.06 |
| Eastman Chemical | 8.2B | 17.58 | 1.38 | 7.99% | 5.42% | 84.41 |
| Arcadium Lithium plc | 6.3B | 64.89 | 1.00 | 2.78% | 10.24% | 14.03 |
Financial data is updated regularly. All figures are in the company's reporting currency.






